Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|May 22, 2014

Kymab Receives $40 Million Investment From Gates Foundation and Wellcome Trust

Kymab receives $40 million investment for clinical development of antibody therapeutics.

Kymab, a monoclonal antibody biopharmaceutical company, has raised $40 million in a Series B financing. The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, each investing $20 million.

The funds will enable Kymab to increase the potential of its kymouse platform and advance its pipeline of therapeutic human monoclonal antibodies in areas of unmet medical need. Kymab will also collaborate with the Gates Foundation and its partners on vaccine antigen discovery R&D with a focus on malaria and HIV. Recent data published in Nature Biotechnology demonstrates that the kymouse technology yields an antibody library constituted from 100 trillion different antibodies, in which rare high-quality antibodies can be selected and developed into therapeutics.

In addition, Kymab will pursue a limited number of collaborations to identify and develop therapeutic antibodies in a range of diseases. Kymab has also developed Kymab Access, a program that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics and vaccines by partnering with Kymab and its kymouse antibody technology.

Source: Kymab

Related to this article

View more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more